Founded to serve patients through transformative medicines

Medicines make better futures possible. Beren is a public benefit corporation built to make life-changing medicines in partnership with patients, caregivers, clinicians, and health systems.

Our commitment

Novel medicines, aligned with patients, accessible to all

For Patients

Our Science

Advancing biology and chemistry to address the root cause of diseases

Learn More

Our quest is just beginning

Beren Therapeutics Announces FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann Pick Disease Type C

February 23, 2026
Press Release

Beren, Through its Subsidiary Mandos, Submits New Drug Application to U.S. FDA for Adrabetadex in Infantile-Onset NPC

December 19, 2025
Press Release

FDA Grants Breakthrough Therapy Designation to Investigational Drug Adrabetadex for Individuals with Infantile-Onset Niemann-Pick Disease Type C

December 9, 2025
Press Release
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please check the input and try again.